Wondering if News on my Favorites page is working??
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Lol, great summary!
Just another day in the jungle! The potential is certainly still here to jump back above .01 & beyond. But predicting when is beyond my powers! I do wish the news would have posted on iHub.
So no chance last night to go over any P's & Q's. Son wanted to see Endgame today so I got tix, then went to a late night showing of Cap'n Marvel. All caught up now, looking forward to the show tonight!
Add some DD, or you not ready to fill that short yet?
Pure manipulation! Blocks are small and close knit, it'll come back up. Games for now
I do love me some Keurig coffee! May be a morning of loaders, not letting it get too high while everyone gets in. Time will tell, but this sucker can fly with little pressure!
A damn roller coaster ride! Off to the Keurig for me..
It can certainly do that pretty easily with any buying pressure
Thinking about going back to bed! Lol
Profit takers & stop losses getting filled. Kinda surprised to see but not totally unexpected. This thing shot up pretty good on low volume, I'm still expecting another pop up. Just not sure when, but I'll be ready!
Good morning ETBI! And good post.. yeah it is a Big deal!
A beer says 3 minutes after open we have at least 3 brand new people posting on the board. Any takers??? 8-P
I'll be digging later, like night owl later, and will post any relevant stuff I find. May have already posted it, but need to dissect...
Off to do real life chit, g'luck All
LoL, thank goodness for Alerts indeed bud! I don't play too many stocks really, as evidenced by my long posting history, but I've seen a stock or two over the past 20+ with like-minded news that went ballistic... I figured why not take a gamble that I can afford to lose! That's Not the Plan though! LOL
The increase in PPS and Volume along with this PR should raise some flags as well from now thru the evening! There really is no telling what could happen here, but it could explode! Definitely not done with the "pop" on this news, but who knows how this will be perceived once it reaches the masses! Glad I have some shares, you should too!
Oh, but i'm no investment adviser. However, I do sell desert bridges.... ;P
ETBI .007 Positive Results of Insulin Mouth Rinse
https://investorshub.advfn.com/Eastgate-Biotech-Corp-ETBI-28110/
Exactly! I plan to reach out again tomorrow mid-morning to see if I can reach someone, we'll see. Nonetheless, the PR's on their company website and previous two SEC filings show they are trying... and today's news shows a Payoff!
Cha=Ching!
ETBI .007 Positive Results of Insulin Mouth Rinse
https://investorshub.advfn.com/Eastgate-Biotech-Corp-ETBI-28110/
An Insulin Mouth Rinse sure beats the hell out of reaching the point of constant needle injections! Never conceived of such a notion, but this PR should disseminate this evening to a wider audience. I'd expect a higher high in the next couple of days!
I also inquired with iHub as to why the news release today is not listed on the board. I know they relay Globe Newswire feeds, so we'll see.
I'm doing my Due Diligence and posting what I feel would be good to get up today during this last hour of trading. I really don't have time to go down your rabbit hole right now. I did just link to the SEC filings. Feel free to dig as well, and if I come up with information you may be looking for all you have to do is buy me a beer!
Power Hour People, this news today is certainly a Catalyst! I did reach out to the company earlier today, but in requesting to speak with IR I was informed that many officers were in a meeting. I bet they were, quite a jump up in SP today! Gonna dig some more tonight, but needless to say, I picked up a few today!
I can only type so fast...
Company Website has CEO Interviews & preceding PR's
http://eastgatebiotech.com/
http://eastgatebiotech.com/investors/press-releases/
EastGate Biotech Announces Positive Phase II Clinical Results of its Innovative Liquid Insulin Mouth Rinse Solution for Type 2 Diabetes
Following a 3-month treatment, significant Hb1c Reduction was observed with administration of a single dose of Insugin two times a day
WEST CALDWELL, NJ and TORONTO, ON, April 24, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- EastGate Biotech Corp. (OTC: PINK: ETBI), a pharmaceutical company, that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of Type 2 diabetes, announced today positive Phase II Clinical Results of its innovative liquid insulin mouth rinse solution for Type 2 diabetes patients.
The 90-day Phase II clinical study was conducted in Pakistan at the Sharif Medical City Hospital (http://www.sharifmedicalcity.org/). Dr. Ayub Latif Khawaja is the Principal Investigator (PI). This ongoing Phase II human clinical trial is estimated to enroll 50 Type 2 patients currently on metformin treatment. Interim results are based on the first 30 patients who took a regiment of 25 IU of Insugin, a recombinant human liquid insulin mouth rinse twice a day at mealtime along with 500 mg of Metformin. The Phase II study assessed safety, tolerability, pharmacokinetics and efficacy. A placebo arm was also incorporated in the clinical protocol.
The study summary and conclusions included:
-Insugin offers unique benefits and the product’s goal is to slow down progression of Type 2 diabetes mellitus and reduce complications;
-Insugin displayed a good safety and tolerability profile;
-Observed a statistically significant decrease in A1c levels after 1 week of treatment in combination with Metformin versus placebo;
-Observed that the most significant HbA1c reduction resulted from administration of a single dose of Insugin (25 IU) two times a day;
-Observed improvements in insulin secretion in Type 2 diabetes patients during hyperglycemic clamp;
-Observed that clinical efficacy of Insugin was non-inferior to Metformin, while its effect on HOMA-IR and fasting insulin level was superior compared to Metformin;
-Prevents the first step of apoptotic cascade (cytochrome C release) and protects cells from dying when submitted to an oxidative stress level (high glucose levels);
-Prevents endothelial dysfunction, which is well correlated to an improvement of atherosclerosis and cardiovascular complications;
-Preserves beta cell mass and beta cell function over time, leading to a potential delay of the disease’s progression;
“While we are excited about all of the findings of this Phase II study with our innovative liquid insulin mouth rinse, we met our primary goal which was to demonstrate the safety and efficacy of Insugin,” says Anna Gluskin, CEO of EastGate Biotech. “My position has always been that insulin is one of the best, if not, the most effective diabetes treatment. A non-injectable formulation of insulin encourages greater patient compliance, and ultimately leads to better maintenance of glucose control. Our liquid insulin mouth rinse may have the ability to maintain better glucose control among Type 2 patients which will slow down the progression of the disease and reduce the incidence of debilitating conditions such as strokes, heart attacks, kidney disease,” concludes Anna Gluskin.
“We are very proud to have conducted the first human Phase II trial in Pakistan,” stated Nasir Irfat, Director of Genome Pharma/Origin Pharma, EastGate’s Joint Venture partner. “The patients in the Phase II trial were very pleased with the results and found the product easy to administer and expressed an overall satisfaction with Insugin.” Nasir Irfat continued, “The actual reduction of HbA1c is key to the regulatory path but the acceptance and demand from diabetes patients will play a role in the marketing plan going forward.”
About EastGate Biotech
EastGate Biotech focuses on innovative technological developments and produces and distributes innovative drug compounds and healthy nutraceuticals that are based on natural therapies absorbed by the body. We utilize advanced nanotechnologies and alternative delivery systems that take difficult to deliver compounds and deliver them using our nanotechnology platform which ultimately increase the bioavailability to the body. Using our methods of delivery provides healthy alternatives to conventional pharmaceuticals that all-too-often create dangerous side-effects and unexpected consequences for those trying to attain and maintain a healthy lifestyle. EastGate's wholly owned subsidiary Omni Surgery and Anti-Aging Centre is the first of many surgery centers to come under the Omni umbrella as we plan to roll up existing business under the Omni brand and expand our footprint globally.
Cautionary statement on forward-looking information
All statements, other than statements of historical fact, contained or incorporated by reference in this news release constitute "forward-looking information" or "forward-looking statements" within the meaning of certain securities laws, including the provisions for "safe harbor" under the United States Private Securities Litigation Reform Act of 1995 and are based on expectations, estimates and projections as of the date of this news release.
The words "anticipates", "plans", "expects", "indicate", "intend", "scheduled", "estimates", "forecasts", "focus", "guidance", "initiative", "model", "methodology", "outlook", "potential", "projected", "pursue", "strategy", "study", "targets", or "believes", or variations of or similar such words and phrases or statements that certain actions, events or results "may", "could", "would", or "should", "might", or "way forward", "will be taken", "will occur" or "will be achieved" and similar expressions identify forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that are inherently subject to significant business, economic and competitive risks, uncertainties and contingencies. The risks, estimates, models and assumptions contained or incorporated by reference in this release, include those identified from time to time in the reports filed by EastGate with the SEC, which should be considered together with any forward-looking statement. EastGate undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT:
Rose Perri
1-647-692-0652
Email: information@eastgatepharmaceuticals.com
Website: www.EastGateBiotech.com
EastGate Biotech Signs Strategic Alliance Agreement with MJ Biopharm for Insulin API Supply
Alliance with MJ Biopharm of Mumbai, India positions the company to further its plans for SEA countries for its liquid insulin mouth rinse
WEST CALDWELL, NJ and TORONTO, ON, March 19, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- EastGate Biotech Corp. (OTC PINK: ETBI), a pharmaceutical company that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of Type 2 diabetes, entered into a long term strategic alliance with MJ Biopharm (www.mjgroup.co.in) for the supply of human recombinant insulin.
One of the key terms of the strategic alliance agreement between EastGate and MJ Biopharm is to provide EastGate with human insulin active pharmaceutical ingredient (API) for clinical trial purposes AT NO COST in order to formulate its liquid insulin mouth rinse in the South East Asian (SEA) territory. The SEA countries included in the agreement are Pakistan, Bangladesh, Malaysia, Philippines, India, Vietnam, Indonesia, Thailand, Singapore, Cambodia, Laos, Myanmar, Brunei, Sri Lanka and Nepal. MJ Biopharm also agrees to provide all regulatory support required to achieve regulatory approval in each country. After approval, MJ Biopharm agreed to provide human insulin API for commercial purposes in the same territory for a period of 10 years. In exchange for the free insulin during the trials, EastGate has agreed to pay MJ Biopharm a royalty after the countries in the territory have received regulatory approval and have launched their marketing campaigns.
In addition, EastGate has given MJ Biopharm a First Right of Refusal on the liquid insulin mouth rinse for the country of India.
According to the International Diabetes Federation (IDF) Diabetes Atlas 8th Edition an estimated 82 million adults aged 20-79 years were living with diabetes in the SEA region in 2017; representing a regional prevalence of 8.5%. About 45.9% of these diabetes cases were undiagnosed.
"This strategic agreement will allow EastGate to quickly roll out our liquid insulin mouth rinse in the SEA territory," said Anna Gluskin, CEO of EastGate Biotech. "Securing a dominant supplier of insulin in this region was the final piece we needed for our go to market strategy. We now have strong regulatory support. We are delighted to see such strong regulatory support from both of our partners in this region. MJ Biopharm has an excellent reputation and standing within the regulatory community, and this is of great value to EastGate. We believe that this represents a new era in the treatment of diabetes," concludes Anna Gluskin.
Rose C. Perri, President of EastGate Biotech, added, "Early on we realized that procuring an exclusive source of insulin was key to our strategic plans for the development and future commercialization of our liquid insulin mouth rinse for Type 2 diabetes patients; particularly in light of the fact that there are very few insulin manufacturers around the world. Together with my colleague, Bill Abajian, in charge of Global Licensing and Business Development, we mapped out a plan to execute our needs specifically in our initial targeted market of South East Asia. This strategic agreement is a direct result of our attendance at the Arab Health Conference at the end of January. Together with the MJ Executive team we were able to reach agreeable terms in order to finalize the agreement expeditiously. We anticipate that this will jump start more licensing agreements in the coming months. Our pathway to regulatory approval in the SEA region is now well defined ahead of our forthcoming clinical trial results."
Amol Shah, Managing Director of MJ Biopharm, says, "MJ has focused on insulin based therapy. Despite its proven efficacy and safety, per capita usage of insulin is low in emerging markets due to "needle fear". We are delighted to work with EastGate as they offer just what we were looking for: development of an innovative delivery system for insulin. This type of collaborative effort will help in providing access to insulin to a larger number of the needle adverse population. MJ Biopharm with its strong capability in manufacturing insulin drug substance will support EastGate's initiative in reversing the tide of Diabetes through an innovative, yet easy-to-administer system for non-invasive drug product."
About MJ Biopharm
MJ Biopharm is headquartered in Mumbai, India and is a subsidiary of the much larger MJ Group of companies. The company's vision is to improve access to life-sustaining therapies and to discover, develop and commercialize quality bio-similar products through technology transfer. Their mission to bring value added cost effective solutions for diabetes is in complete alignment with EastGate. They have 14,000 square meters of manufacturing space that has been built to European Medicines Evaluation Agency (EMEA) and Food and Drug Administration (FDA) standards. Their microbial unit is devoted to the production of recombinant human insulin and analogs and represents one of their three manufacturing facilities. They are one of the largest manufacturers of human insulin formulations in different forms.
About EastGate Biotech
EastGate Biotech focuses on innovative technological developments and produces and distributes innovative drug compounds and healthy nutraceuticals that are based on natural therapies absorbed by the body. We utilize advanced nanotechnologies and alternative delivery systems that take difficult to deliver compounds and deliver them using our nanotechnology platform which ultimately increase the bioavailability to the body. Using our methods of delivery provides healthy alternatives to conventional pharmaceuticals that those trying to attain and maintain a healthy lifestyle. EastGate's wholly-owned subsidiary OMNI Surgery and Anti-Aging Centre is the first of many surgery centers to come under the OMNI umbrella as we plan to roll up existing businesses under the OMNI brand and expand our footprint globally.
Cautionary statement n forward-looking information
All statements, other than statements of historical fact, contained or incorporated by reference in this news release constitute "forward-looking information" or "forward-looking statements" within the meaning of certain securities laws, including the provisions for "safe harbor" under the United States Private Securities Litigation Reform Act of 1995 and are based on expectations, estimates and projections as of the date of this news release.
The words "anticipates", "plans", "expects", "indicate", "intend", "scheduled", "estimates", "forecasts", "focus", "guidance", "initiative", "model", "methodology", "outlook", "potential", "projected", "pursue", "strategy", "study", "targets", or "believes" or variations of or similar such words and phrases or statements that certain actions, events or results "may", "could", "would" or "should", "might" or "way forward", "will be taken", "will occur" or "will be achieved" and similar expression identify forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that are inherently subject to significant business, economic and competitive risks, uncertainties and contingencies. The risks, estimates, models and assumptions contained or incorporated by reference in this release, including those identified from time to time in the reports filed by EastGate with the SEC, which should be considered together with any forward-looking statement. EastGate undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT:
Rose C. Perri
1-647-692-0652
Email: information@eastgatepharmaceuticals.com
Website: www.EastGateBiotech.com
EastGate Biotech Attends Arab Health Conference Seeking Additional Joint Venture Partnerships
EastGate Biotech to Showcase Insulin Products at the Dubai World Trade Centre
WEST CALDWELL, NJ and TORONTO, ON, Jan. 30, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- EastGate Biotech Corp. (OTC PINK: ETBI), a pharmaceutical company that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of type 2 diabetes, is pleased to announce that key advisor William Abajian will represent the company at the Arab Health conference in Dubai. Abajian is EastGate’s key advisor with regard to business development and licensing as well as mergers and acquisitions. Also attending the show is our JV Partner Netris/Origin Biopharmaceuticals from Pakistan.
With more than 84,500 healthcare and trade professionals from 160 countries, EastGate Biotech will have the opportunity to visit 4,150 exhibiting companies from 66 countries whom are expected to convene at the Dubai World Trade Centre from 28th – 31st January 2019, for the 44th edition of the exhibition. Arab Health provides an important platform for the company to develop a footprint within the MENA healthcare industry and build relationships with international stakeholders and facilitators whom explore new business opportunities in the global healthcare field.
“The Arab Health Conference is the perfect venue for EastGate to network and build foundations for future partnership,” said Bill Abajian. “This is the largest healthcare conference of its kind in the Middle East which also happens to be a hot spot of diabetes that affects over 39 million diagnosed in the region. The conference also attracts many attendees from South East Asia which happens to be two major geographic regions in our target market. Innovation is the theme of this conference and our oral insulin mouth rinse has the potential to be the biggest innovation to hit the market with a low-cost effective treatment to control the diabetes epidemic. We expect to do really well at this show. I have been very busy setting appointments primarily with diabetes management companies and the participants I have already talked to understand the potential of the oral insulin mouth rise. Having our JV partner from Pakistan by our side will add to our relevance as they can speak toward the efficacy of the product.”
“We are so fortunate to have both our JV partner and Bill represent EastGate at the conference,” said Anna Gluskin, CEO of EastGate Biotech. “Not only can they spread the word of a paradigm changing way to treat the diabetes epidemic, but they can sit down with decision makers and set the framework for future collaborations. We are looking for additional joint venture deals and collaborations. Our approach is to license the world piece by piece. Bill has a gift of going to these shows and getting people very excited about our technology and has always come back with great leads and in some cases licensing agreements. The show appears to be going quite well and we hope this translates into more Joint Venture partnerships in the near future. I am very proud of the team we have been able to cultivate at EastGate.”
About Arab Health
Arab Health prides itself as the leading healthcare business platform in the Middle East. Connecting manufacturers and service providers with clinicians, procurement professionals, dealers and distributors is the primary goal of the event. Leverage the success of the show and make key business contacts by utilizing our multiple channels to connect you to the region’s healthcare industry. For 44 years Arab Health has brought you the latest innovations in healthcare. From state-of-the-art imaging equipment to the most cost-effective disposables; developments in surgery to advances in prosthetics, Arab Health continues to be at the heart of healthcare in the Middle East. As the largest collection of healthcare product manufacturers and service providers under one roof, Arab Health is your one-stop shop for all your healthcare sourcing and procurement needs. With thousands of products to explore, coming in from more than 68 countries, make sure you don’t miss this essential business event. The show is free to visit.
About EastGate Biotech
EastGate Biotech focuses on innovative technological developments and produces and distributes innovative drug compounds and healthy nutraceuticals that are based on natural therapies absorbed by the body. We utilize advanced nanotechnologies and alternative delivery systems that take difficult to deliver compounds and deliver them using our nanotechnology platform which ultimately increase the bioavailability to the body. Using our methods of delivery provides healthy alternatives to conventional pharmaceuticals that all-too-often create dangerous side-effects and unexpected consequences for those trying to attain and maintain a healthy lifestyle. EastGate's wholly owned subsidiary Omni Surgery and Anti-Aging Centre is the first of many surgery centers to come under the Omni umbrella as we plan to roll up existing business under the Omni brand and expand our footprint globally.
About Netris / Origin Biopharmaceutical
Netris / Origin Biopharmaceutical has been registered with the Pakistan Ministry of Health since 2002 and is licensed for distribution, marketing, importing and supplying the Government with therapeutic drugs. Netris Bio looks to capitalize on cutting edge technologies and take advantage of emerging trends in the pharmaceutical industry to quickly and safely bring drugs to the Pakistan market. Netris Bio has a team of 167 highly dedicated professionals that allow the company to get more done with less to its highly collaborative work environment that resembles more of a big family than a biotech company. The company currently markets Citlicolin injections, Pantoprazole infusions, omeprazole, heparine, enoxparine, cephalosporin, anti-cancer, and cardiac. In addition, the company collects blood plasma and markets biologics, vaccines, nutraceuticals, and Nuro products.
Cautionary statement on forward-looking information
All statements, other than statements of historical fact, contained or incorporated by reference in this news release constitute "forward-looking information" or "forward-looking statements" within the meaning of certain securities laws, including the provisions for "safe harbor" under the United States Private Securities Litigation Reform Act of 1995 and are based on expectations, estimates and projections as of the date of this news release.
The words "anticipates", "plans", "expects", "indicate", "intend", "scheduled", "estimates", "forecasts", "focus", "guidance", "initiative", "model", "methodology", "outlook", "potential", "projected", "pursue", "strategy", "study", "targets", or "believes", or variations of or similar such words and phrases or statements that certain actions, events or results "may", "could", "would", or "should", "might", or "way forward", "will be taken", "will occur" or "will be achieved" and similar expressions identify forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that are inherently subject to significant business, economic and competitive risks, uncertainties and contingencies. The risks, estimates, models and assumptions contained or incorporated by reference in this release, include those identified from time to time in the reports filed by EastGate with the SEC, which should be considered together with any forward-looking statement. EastGate undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT:
Rose Perri
1-647-692-0652
Email: information@eastgatepharmaceuticals.com
Website: www.EastGateBiotech.com
EastGate Biotech Appoints Additional Consultants in Preparation of Progressing Company Developments in 2019
WEST CALDWELL, N.J. and TORONTO, Dec. 19, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE-- EastGate Biotech Corp. (OTC PINK: ETBI), a pharmaceutical company that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of type 2 diabetes, appointed key consultants Saul A. Mashaal, PhmB, MBA and Munaf Ali, PhD to assist in regulatory matters and manufacturing of the company's liquid insulin mouth rinse solution for Type 2 diabetes and pre-diabetes patients.
Saul Mashaal has over 40 years of biotech experience. He has a degree in pharmacy and an MBA. His subject matter expertise is in the area of biotech manufacturing, pharmaceutical distribution, clinical trial development, and insulin manufacturing which are of great interest to EastGate. Saul was instrumental in the building of major biotechnology insulin manufacturing facilities in Israel, China, India and the UAE, the size and scope of the projects exceeded $500 million. Saul was the founder and Chairman of Acertus Pharma LLC and the founder and Chairman of the SciTech Group. Acertus is a privately held company that focuses on the distribution of biopharmaceuticals and consumer products. SciTech Group morphed into a showcase company in Singapore to implement research and development and manufacturing in Singapore. During his tenure, the company developed a breakthrough vaccine for immunization against Hepatitis B and spun off the Bioton division which was one of the first 4 companies in the world to produce recombinant human insulin. He is no stranger to the public markets. Bioton was a Polish company listed on the Warsaw Stock Exchange and his predecessor company, SciTech was listed on the Australian Stock Exchange. Early in his career at 3M he was head of business development and the clinical research group and managed 27 clinical trials in the United States and Europe. Saul’s depth of experience in key areas that EastGate is starting to address, make him an ideal consultant.
“EastGate has a paradigm changing drug for type 2 diabetes,” said Saul Mashaal. “Injections are not the way to address the compliance problem worldwide. An inexpensive easy to use drug that has demonstrated efficacy is a great first step. Having worked at big pharma, I have seen the strategies they have employed to introduce new diabetes drugs, and after the price fixing scandal there was a huge loss of confidence. Therein lies the opportunity for EastGate. Given my background in manufacturing, I anticipate the EastGate team will utilize my contacts in Singapore to negotiate long term supply contracts of insulin. Having reviewed EastGate’s clinical trial plan, I believe they are on the right trajectory and will eventually need my assistance in developing distribution following drug approval.”
Dr. Munaf Ali has over 25 years of experience in regulatory affairs and CNS (specifically in Parkinson disease, Alzheimer’s disease, depression, schizophrenia, and neuropathic pain). He is very familiar with the role insulin plays in these diseases. He is also no stranger to providing scientific and regulatory strategic advice for the conduct of clinical trials across many therapeutic areas. He has been involved on a strategic level with 46 different countries providing guidance with various global regulatory agencies, most notably the FDA and EMA on behalf of sponsors involved in developing the clinical trials necessary for registration. He worked as the head of regulatory strategies for expediting the development of CNS drugs at Ingenix which was eventually acquired by the United Healthcare Group. He now works as an independent consultant providing Pharmaceutical and Biotech companies, CROs, Universities and Financial Institutions guidance on the regulatory pathway for clinical trial development. To his credit, he has been involved in over 10 INDs, 8 NDAs and MAAs, and 5 Orphan Drug Applications. He has presented at FDA Advisory Committee Meetings, CPMP hearings, and at regulatory meetings in Europe, Asia, Central and South America.
“EastGate has a monumental task ahead of it when we look at the size and scope of the global epidemic in diabetes” said Dr. Ali. “Each country has a different regulatory body and different approval requirements. This is a virtual minefield, and the only way to navigate it is through experience. I couldn’t be more pleased to be part of the EastGate team single handedly tackling this global epidemic. I hope to quickly and efficiently establish a global regulatory strategy that charts a course toward the quickest approvals so that we can bring a much-needed drug into the fight against this epidemic.”
“Our team at EastGate is growing,” said Anna Gluskin, CEO of EastGate Biotech. “We have been able to attract the world’s best and brightest to this team because each of them realizes that something needs to be done to solve this global epidemic or the burden on our healthcare systems is going to collapse under its own weight. It also helps that we have such a simple and elegant solution. An oral insulin mouth rinse designed to supplement the pancreas and stave off the side effects of diabetes that burden the healthcare system. I am confident that this team will help us realize our goal of our first approval in 2019.”
About EastGate Biotech
EastGate Biotech focuses on innovative technological developments and produces and distributes innovative drug compounds and healthy nutraceuticals that are based on natural therapies absorbed by the body. We utilize advanced nanotechnologies and alternative delivery systems that take difficult to deliver compounds and deliver them using our nanotechnology platform which ultimately increase the bioavailability to the body. Using our methods of delivery provides healthy alternatives to conventional pharmaceuticals that all-too-often create dangerous side-effects and unexpected consequences for those trying to attain and maintain a healthy lifestyle. EastGate's wholly owned subsidiary Omni Surgery and Anti-Aging Centre is the first of many surgery centers to come under the Omni umbrella as we plan to roll up existing business under the Omni brand and expand our footprint globally.
Cautionary statement on forward-looking information
All statements, other than statements of historical fact, contained or incorporated by reference in this news release constitute "forward-looking information" or "forward-looking statements" within the meaning of certain securities laws, including the provisions for "safe harbor" under the United States Private Securities Litigation Reform Act of 1995 and are based on expectations, estimates and projections as of the date of this news release.
The words "anticipates", "plans", "expects", "indicate", "intend", "scheduled", "estimates", "forecasts", "focus", "guidance", "initiative", "model", "methodology", "outlook", "potential", "projected", "pursue", "strategy", "study", "targets", or "believes", or variations of or similar such words and phrases or statements that certain actions, events or results "may", "could", "would", or "should", "might", or "way forward", "will be taken", "will occur" or "will be achieved" and similar expressions identify forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that are inherently subject to significant business, economic and competitive risks, uncertainties and contingencies. The risks, estimates, models and assumptions contained or incorporated by reference in this release, include those identified from time to time in the reports filed by EastGate with the SEC, which should be considered together with any forward-looking statement. EastGate undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT:
Rose Perri
1-647-692-0652
Email: information@eastgatepharmaceuticals.com
Website: www.EastGateBiotech.com
SOURCE: EastGate Biotech Corp.
I sought this board out as well when I was looking for some advice/opinion. Doesn't seem this is the place to get any!
Happy 420 Day!
Great story!
If the last bit of NK correspondence posted here is the case, not a damn thing matters in regards to any other company's worth! Pixel cannot even earn enough for their parent company to complete an audit. Kind of hard to believe if you ask me. I'm just curious who will initiate the class-action lawsuit against all involved if we don't start getting some clarification on or about SOON!
Been a long time since I've added to my position here, but just did!
Gluk
$SNSGF just posted a 15-12g last week. I'm not familiar with this at all, but I am curious; could this be an avenue by which they could use to be bought out by another company? Tia
When you decide to have a few posters added to your ignore list, it sure appears 33 is talking to himself!
I'm holding, not writing off any of my shares.
Golden
PIXL
WTH?? SNSGF
That's certainly relevant.. Hopefully Pixelmags seizes the opportunity and puts a bit of funds into ad placement for their ReadR app!
Appreciate the response, I simply have a hard time believing PxL isn't making $ hand over fist what with all their relationships & background dealings in so very many digital magazines across most all popular forums!